vaccine

4 Latest Facts About Johnson & Johnson's Investigational COVID-19 Vaccine

Summary: 

A preclinical study just published in Nature shows that the company's investigational vaccine has shown positive early data for eliciting an immune response against SARS-CoV-2, the virus that causes COVID-19. We share more about the findings from the recent preclinical study, along with other up-to-date information about the potential vaccine candidate.

Blog

A preclinical study just published in Nature shows that the company's investigational vaccine has shown positive early data for eliciting an immune response against SARS-CoV-2, the virus that causes COVID-19. We share more about the findings from the recent preclinical study, along with other up-to-date information about the potential vaccine candidate.

Johnson & Johnson and Its Partners Mark a Milestone in the Quest for a Global Preventive HIV Vaccine With the Imbokodo Study

The clinical trial has completed full immunizations of the company's investigational HIV vaccine regimen. Learn what this means for the future of fighting the disease—and also for the creation of a potential vaccine for COVID-19.
Blog

Since the start of the pandemic, Johnson & Johnson has been working to help address the devastating impacts of COVID-19 through the power of its science, the size of its global reach—and the know-how that comes from such experiences as standing up to challenges like HIV.

“I Was Working on a Potential COVID-19 Vaccine—Then My Wife Got Sick”: Meet a Researcher Whose Personal Experience Is Fueling His Fight Against the Pandemic

Within a matter of weeks, Ramon Polo's work and home life were completely changed by the novel coronavirus—and he's a stronger scientist and husband for it.
Blog

In late January—weeks before many people had even heard of the novel coronavirus—Ramon Polo, PharmD, Ph.D., started to work on finding solutions to fight the virus, which data suggested had the potential to become a global pandemic.

As the Vice President of Regulatory Affairs for Infectious Diseases and Vaccines and Global Public Health at Johnson & Johnson, Dr. Polo quickly began to focus on working with healthcare authorities across the globe to collaborate on the development of both therapeutic treatments and a potential vaccine for the rapidly spreading novel coronavirus.

The Road to a Vaccine, Season 2, Ep. 2: How New COVID-19 Outbreaks Are Impacting a Global Return to Normal

Multimedia with summary

In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.

In Episode 2, Lisa Ling talks with Dr. Francis Collins, Director, NIH about the latest on treatments and vaccines. Also, Harvard's Dr. Ashish Jha shares how the virus affects the body and Johns Hopkins' Dr. Tom Inglesby explains what the new data on spread means for people.

The Road to a Vaccine, Season 2, Ep. 1: How Lessons Learned in Fighting HIV Help Us Battle COVID-19

Multimedia with summary

In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.

In the Season 2 premiere, Lisa Ling checks into the AIDS 2020 conference to talk with HIV advocate Laverne Cox and Johnson &. Johnson Chief Scientific Officer Paul Stoffels, M.D., about how HIV vaccine research is informing work on COVID-19 vaccines.

5 Latest Facts About Johnson & Johnson's Ebola Vaccine

As the European Commission grants Marketing Authorization for the company's Ebola vaccine regimen—a key step towards enabling broader access to it for the people who need it most—we share top facts about the vaccine for the deadly virus.
Blog

One of the world's deadliest viral diseases was discovered in 1976 in Zaire, now known as the Democratic Republic of the Congo (DRC), near the Ebola River.

Since then, there have been 30 outbreaks of Ebola Virus Disease (EVD)—the worst of which hit in West Africa in 2014. During that two-year epidemic, more than 11,000 people died in Guinea, Liberia and Sierra Leone. Two in five individuals who were infected with the disease, then lost their lives.

The Road to a Vaccine, Ep. 8: What Two Renowned Virus Hunters Want Us to Know About COVID-19

Multimedia with summary

This new eight-episode educational video series will examine the latest efforts to respond to the COVID-19 pandemic and break down the complex process of developing a vaccine.

Each week our host Lisa Ling will talk to leading scientists and researchers, healthcare workers on the front lines and public health experts around the world working collaboratively to help bring an end to the deadly pandemic.

The Road to a Vaccine, Ep. 6: How the Global Community Is Coming Together to Battle COVID-19

Multimedia with summary

This new eight-episode educational video series will examine the latest efforts to respond to the COVID-19 pandemic and break down the complex process of developing a vaccine.

Each week our host Lisa Ling will talk to leading scientists and researchers, healthcare workers on the front lines and public health experts around the world working collaboratively to help bring an end to the deadly pandemic.

The Road to a Vaccine, Ep. 4: What Doctors on the Front Lines of COVID-19 Are Now Saying About the Virus

Multimedia with summary

This new eight-episode educational video series will examine the latest efforts to respond to the COVID-19 pandemic and break down the complex process of developing a vaccine.

Each week our host Lisa Ling will talk to leading scientists and researchers, healthcare workers on the front lines and public health experts around the world working collaboratively to help bring an end to the deadly pandemic.

She's a Scientist With One of the World's Most Important Jobs: Creating a Potential COVID-19 Vaccine

By Hanneke Schuitemaker, Ph.D., as told to Liz Ozaist, Global Content Lab Editor-in-Chief, Johnson & Johnson
Blog

She has spent her career investigating some of the world's most pervasive infectious diseases—HIV and Ebola, just to name a couple—and now Hanneke Schuitemaker, Ph.D., is fighting a virus that could very well define her career.

Pages

Subscribe to vaccine